Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.73 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.73 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.73 |
| ▸ | PGR | P06401 | 1/20 | 0.73 |
| ▸ | HTR1A | P08908 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | AR | P10275 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31497041 | 0.85 | PTGS2 (0.64) | TTRMEN1PTGS2AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL29484181 | 0.84 | MT-CO2 (1.00) | TTRMEN1PTGS2AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL25190 | 0.84 | MT-CO2 (1.00) | TTRMEN1PTGS2AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL29389998 | 0.84 | MT-CO2 (1.00) | TTRMEN1PTGS2AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL8060884 | 0.84 | MT-CO2 (1.00) | TTRMEN1PTGS2AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL27540385 | 0.83 | MT-CO2 (0.97) | TTRMEN1PTGS2AKR1C3KMT2A | |
| SCHEMBL11110672 | 0.82 | TTR (0.68) | TTRMEN1PTGS2AKR1C3KMT2A | |
| SCHEMBL11186246 | 0.81 | MEN1 (0.71) | TTRMEN1PTGS2AKR1C3KMT2A | |
| Clofenamic Acid SCHEMBL1477650 | 0.81 | PBRM1 (0.73) | TTRMEN1PTGS2AKR1C3KMT2A | |
| Clofenamic Acid SCHEMBL29900200 | 0.81 | PBRM1 (0.73) | TTRMEN1PTGS2AKR1C3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684681-B1 | A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS | ORYXE (US) | 2018-10-24 | — | — | EP | claimed |
| US-9682070-B2 | Method and compositions for treatment or prevention of inflammatory conditions | UNIVERSITY OF ROCHESTER (US) | 2017-06-20 | — | — | US | claimed |
| US-20160256444-A1 | METHOD AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS | UNIV ROCHESTER (US) | 2016-09-08 | — | — | US | claimed |
| EP-1765310-B1 | A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS | ORYXE (US) | 2015-10-28 | — | — | EP | claimed |
| WO-2014024193-A1 | COMPOSITIONS AND METHODS FOR RAPID TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL INGREDIENTS | PRODEL PHARMA LTD. (IL) | 2014-02-13 | — | — | WO | claimed |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | DYNAMIS THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | claimed |
| US-20100221340-A1 | METHOD AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS | UNIVERSITY OF ROCHESTER (US) | 2010-09-02 | — | — | US | claimed |
| EP-2203057-A1 | METHOD AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS | University Of Rochester (US) | 2010-07-07 | — | — | EP | claimed |
| US-20100086495-A1 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSMUCOSAL DELIVERY | DERMA-YOUNG LTD. (IL) | 2010-04-08 | — | — | US | claimed |
| EP-2114384-A2 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSMUCOSAL DELIVERY | Derma-Young Ltd. (IL) | 2009-11-11 | — | — | EP | claimed |
| WO-2006041538-A2 | A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS | ORYXE (US) | 2006-04-20 | — | — | WO | claimed |
| WO-2005039464-A1 | TRANSDERMAL HIGH AND LOW MOLECULAR WEIGHT COMPOUNDS | ORYXE (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050019384-A1 | Mixture for transdermal delivery of low and high molecular weight compounds | ORYXE ENERGY INTERNATIONAL, INC. | 2005-01-27 | — | — | US | claimed |
| US-20040170676-A1 | Mixture for transdermal delivery of low and high molecular weight compounds | JRX BIOTECHNOLOGY, INC. | 2004-09-02 | — | — | US | claimed |
| US-6759056-B2 | FOR THERAPEUTIC AND COSMETIC APPLICATION | ORYXE | 2004-07-06 | — | — | US | claimed |
| US-20030064093-A1 | Mixture for transdermal delivery of low and high molecular weight compounds | JRX BIOTECHNOLOGY, INC. | 2003-04-03 | — | — | US | claimed |
| EP-0252033-B1 | A \"GEL\" PHARMACEUTICAL FORM CONTAINING N-(2.6-DICHLORO-M-TOLIL)-ANTHRANILIC ACID (MECHLOPHENAMIC ACID) FOR USE IN THERAPY BY TOPICAL APPLICATION | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1990-12-27 | — | — | EP | claimed |
| EP-0130524-B1 | DEPOT ANTIPHLOGISTICS | Troponwerke GmbH & Co. KG (DE) | 1989-08-23 | — | — | EP | claimed |
| EP-0252033-A2 | A \"gel\" pharmaceutical form containing N-(2.6-Dichloro-M-Tolil)-Anthranilic acid (mechlophenamic acid) for use in therapy by topical application | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1988-01-07 | — | — | EP | claimed |
| US-4594357-A | Depot antiinflammatory agents | TROPONWERKE GMBH & CO. (DE) | 1986-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256444-A1 | METHOD AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS | ACE, ACE2, MMP1 | TTR 269/4885MEN1 2620/4885PTGS2 124/4885 |
| US-20100221340-A1 | METHOD AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS | ACE, ACE2, MMP1 | TTR 269/4885MEN1 2620/4885PTGS2 124/4885 |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | FN3K, ROS1, FN3KRP | TTR 3404/4885MEN1 4765/4885PTGS2 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.